Alan F. Denenberg

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by Bloom Energy Corporation of $200 million aggregate principal amount of its 2.500% green convertible…

Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited…

Davis Polk advised the representatives of the several underwriters in connection with a debut SEC-registered bond offering by ServiceNow, Inc. of $1.5 billion aggregate principal amount of…

Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…

Davis Polk advised the joint book-running managers on an SEC-registered debt offering by Alphabet Inc., consisting of $1 billion of 0.450% notes due 2025, $1 billion of 0.800% notes…

Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…

Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

 Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by II-VI Incorporated of 10,697,570 shares of its common stock for an…